Publications by authors named "P Bittigau"
Background: To identify outcome predictors of selective dorsal rhizotomy (SDR) in children with spastic cerebral palsy (CP) using logistic regression models.
Methods: A retrospective single-center study was conducted on children with spastic CP who had undergone SDR. Two outcomes were defined, one representing children not improving in motor function and spasticity and one representing children improving in motor function two years after surgery.
Article Synopsis
- A novel mutation (c.3506G>A, p.G1169D) in the Ca1.3 gene is linked to a syndrome that causes autism, developmental delays, and other neurological and hormonal disorders in children, presenting with varying severities.
- Two patients with this mutation exhibited different symptoms: one had severe issues including respiratory problems and hearing loss, while the other had a milder phenotype possibly due to mosaicism of the mutation.
- Functional studies showed that the mutation enhances channel activity, leading to abnormal calcium channel behavior, but treatments with calcium channel blockers (isradipine and nifedipine) did not produce positive effects for the severely affected patient.
Objective: In the fourth year of the COVID-19 pandemic, mortality rates decreased, but the risk of neuropsychiatric disorders remained the same, with a prevalence of 3.8% of pediatric cases, including movement disorders (MD) and ataxia.
Methods: In this study, we report on a 10-year-old girl with hemichorea after SARS-CoV-2 infection and immunostained murine brain with patient CSF to identify intrathecal antibodies.
Ophelia syndrome is characterized by the coincidence of severe neuropsychiatric symptoms, classical Hodgkin lymphoma, and the presence of antibodies to the metabotropic glutamate 5 receptor (mGluR5). Little is known about the pathogenetic link between these symptoms and the role that anti-mGluR5-antibodies play. We investigated lymphoma tissue from patients with Ophelia syndrome and with isolated classical Hodgkin lymphoma by quantitative immunocytochemistry for mGluR5-expression.
View Article and Find Full Text PDFIntroduction: In one third of all patients with epilepsy, seizure freedom is not achieved through anti-seizure medication (ASM). These patients have an increased risk of earlier death, poorer cognitive development, and reduced quality of life. Cenobamate (CNB) has recently been approved as a promising novel ASM drug for the treatment of adults with focal-onset epilepsy.
View Article and Find Full Text PDF